TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives

January 4, 2024

https://www.globenewswire.com/news-release/2024/01/04/2803986/0/en/TransCode-Therapeutics-Publishes-Open-Letter-Outlining-Company-s-Progress-and-Objectives.html

BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (“TransCode” or the “Company”) (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced publication of an open letter to shareholders outlining the Company’s progress in 2023 and objectives in 2024. The text of the letter is below.

Read more at globenewswire.com

Related news for (RNAZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.